Friday, April 24, 2015 9:20:07 AM
On May 23, 2014, the Company entered into a securities purchase agreement pursuant to which the Company issued a 10% convertible promissory note in the aggregate principal amount of up to $500,000, to be advanced in amounts at the lender’s discretion. Upon closing of the transaction the Company received an advance of $50,000. The Company received additional advances in the amount of $300,000 for an aggregate sum of $350,000. The note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of the lesser of $0.0048 per share or fifty percent (50%) of the lowest trading price after the effective date of each respective advance. The note matures six (6) months from the effective dates of each respective advance. The maturity dates in respect to each advance is from May 2015 through December 2015. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $105,890 during the six months ended December 31, 2014.
http://ih.advfn.com/p.php?pid=nmona&article=65431795
Recent HYSR News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 09:31:40 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/02/2024 05:15:09 AM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 01/25/2024 09:40:59 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/24/2024 09:32:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 08:28:16 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2023 09:03:04 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/29/2023 08:33:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2023 08:13:34 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM